Literature DB >> 32430997

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference.

Josep M Llovet1,2,3, Augusto Villanueva1, Jorge A Marrero4, Myron Schwartz1, Tim Meyer5, Peter R Galle6, Riccardo Lencioni7,8, Tim F Greten9, Masatoshi Kudo10, Sumithra J Mandrekar11, Andrew X Zhu12,13, Richard S Finn14, Lewis R Roberts15.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32430997     DOI： 10.1002/hep.31327

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  44 in total

1.  Reply to the Letter "Comment on Regarding Manuscript 'Treatment of Intermediate Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies'".

Authors:  Kazuhiro Nouso; Kazuya Kariyama
Journal:  Liver Cancer       Date:  2021-03-11       Impact factor: 11.740

2.  Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma.

Authors:  Kazufumi Kobayashi; Sadahisa Ogasawara; Aya Takahashi; Yuya Seko; Hidemi Unozawa; Rui Sato; Shunji Watanabe; Michihisa Moriguchi; Naoki Morimoto; Satoshi Tsuchiya; Kenji Iwai; Masanori Inoue; Keita Ogawa; Takamasa Ishino; Terunao Iwanaga; Takafumi Sakuma; Naoto Fujita; Hiroaki Kanzaki; Keisuke Koroki; Masato Nakamura; Naoya Kanogawa; Soichiro Kiyono; Takayuki Kondo; Tomoko Saito; Ryo Nakagawa; Eiichiro Suzuki; Yoshihiko Ooka; Shingo Nakamoto; Akinobu Tawada; Tetsuhiro Chiba; Makoto Arai; Tatsuo Kanda; Hitoshi Maruyama; Kengo Nagashima; Jun Kato; Norio Isoda; Takeshi Aramaki; Yoshito Itoh; Naoya Kato
Journal:  Liver Cancer       Date:  2021-12-06       Impact factor: 11.740

3.  Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kazuya Kariyama; Hidenori Toyoda; Satoshi Yasuda; Kunihiko Tsuji; Takeshi Hatanaka; Satoru Kakizaki; Atsushi Naganuma; Toru Ishikawa; Toshifumi Tada; Koichi Takaguchi; Ei Itobayashi; Noritomo Shimada; Hiroshi Shibata; Takaaki Tanaka; Akemi Tsutsui; Takuya Nagano; Michitaka Imai; Shinichiro Nakamura; Kazuhiro Nouso
Journal:  Oncology       Date:  2021-11-29       Impact factor: 2.935

4.  Initial Experience of Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma in Clinical Practice.

Authors:  Teiji Kuzuya; Naoto Kawabe; Senju Hashimoto; Ryoji Miyahara; Takuji Nakano; Kazunori Nakaoka; Hiroyuki Tanaka; Yohei Miyachi; Arisa Mii; Yoshinao Tanahashi; Yutaro Kato; Atsushi Sugioka; Yoshiki Hirooka
Journal:  Cancer Diagn Progn       Date:  2021-05-03

5.  Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2).

Authors:  Masatoshi Kudo; Richard S Finn; Manabu Morimoto; Kun-Ming Rau; Masafumi Ikeda; Chia-Jui Yen; Peter R Galle; Josep M Llovet; Bruno Daniele; Ho Yeong Lim; David W McIlwain; Reigetsu Yoshikawa; Kenichi Nakamura; Kun Liang; Chunxiao Wang; Paolo Abada; Ryan C Widau; Andrew X Zhu
Journal:  Liver Cancer       Date:  2021-07-12       Impact factor: 11.740

6.  Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.

Authors:  Takeshi Hatanaka; Satoru Kakizaki; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Noritomo Shimada; Kazuhito Kawata; Hisashi Kosaka; Takaaki Tanaka; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Takashi Kumada
Journal:  Hepatol Int       Date:  2022-06-24       Impact factor: 9.029

7.  Efficacy of Superselective Conventional Transarterial Chemoembolization Using Guidance Software for Hepatocellular Carcinoma within Three Lesions Smaller Than 3 cm.

Authors:  Shiro Miyayama; Masashi Yamashiro; Rie Ikeda; Junichi Matsumoto; Kiyotaka Takeuchi; Naoko Sakuragawa; Teruyuki Ueda; Taku Sanada; Kazuo Notsumata; Takuro Terada
Journal:  Cancers (Basel)       Date:  2021-12-19       Impact factor: 6.639

8.  A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2021-10-12       Impact factor: 11.740

9.  Transmediastinal, intrapericardial inferior vena cava approach based on anatomical landmarks for hepatectomy using total hepatic vascular exclusion.

Authors:  Taiji Tohyama; Kei Tamura; Akihiro Takai; Kazuhisa Nishimura; Teruhito Kido; Yasutsugu Takada
Journal:  Langenbecks Arch Surg       Date:  2021-08-24       Impact factor: 2.895

Review 10.  Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?

Authors:  Ti Zhang; Philippe Merle; Huaqi Wang; Haitao Zhao; Masatoshi Kudo
Journal:  Hepatobiliary Surg Nutr       Date:  2021-04       Impact factor: 8.265
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.